Despite supply shortages, the drugs by the two companies saw their sales surge in the first quarter of the year, and competitors are still trying to catch up.t’s not often that a class of chemical becomes a household name, but glucagon-like peptide-1, aka GLP-1, has achieved that status.
Jørgensen said he’s not too concerned about the competition yet. By the time a company gets to late-stage clinical trials, “you’re already too late,” he said. “It takes several years to build the kind of capacity you’re dealing with here, so it’s a daunting task to get it all in place.” Both companies are also looking to refine and develop what they hope are new and better versions. Lilly has new obesity drugs in its clinical development pipeline, including a monoclonal antibody treatment for obesity, as well as another potential new treatment that’s a different class of drug than GLP-1s but behaves similarly.with biotech company Metaphore to develop two new therapeutics in a deal potentially worth up to $600 million.
Malaysia Malaysia Latest News, Malaysia Malaysia Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: CNBC - 🏆 12. / 72 Read more »
Source: Forbes - 🏆 394. / 53 Read more »